Dr. Lacro is clinically trained in dysmorphology/clinical genetics as well as pediatric cardiology. He directs the Cardiovascular Genetics Clinic and the Marfan Syndrome and Related Disorders Program, which provide cardiac and genetic services to patients and families with a variety of genetic conditions including Marfan syndrome, other connective tissue disorders, bicuspid aortic valve and other aortopathies, and Williams syndrome. Dr. Lacro is on the staff of the Echocardiography Laboratory, which provides a full range of imaging studies including transesophageal and fetal examinations. He was a Schwartz Center Fellow in Pastoral Care in 2002 and has an interest in spiritual assessment and spiritual care. Research interests include pathogenesis of congenital cardiovascular malformations and management of patients with multiple malformation syndromes such as Marfan syndrome, other connective tissue disorders, and Williams syndrome. Dr. Lacro was a principal investigator for a multicenter, randomized clinical trial sponsored by the Pediatric Heart Network and the National Heart, Lung, and Blood Institute of the NIH, comparing beta blocker therapy (atenolol) and angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome.